8-KMaterial Agreements

DEXCOM INC 8-K Report, Material Agreement (Apr 8, 2008)

Filed April 8, 2008For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on April 8, 2008, to report a material definitive agreement entered into on April 3, 2008. The Company has entered into a Manufacturing and Supply Agreement with PTG Medical LLC (PTG) for the exclusive supply of certain polymers crucial for synthesizing their polymeric membranes used in their SEVEN continuous glucose monitoring system. This agreement is significant as it secures an exclusive, worldwide, royalty-free, and irrevocable license for DexCom to utilize these polymers in the field of continuous glucose monitoring. The term of the agreement is three years, providing DexCom with a stable and exclusive supply chain for a key component of their technology, which is vital for the production and ongoing development of their SEVEN system.

Key Highlights

  • 1DexCom, Inc. entered into a Material Definitive Agreement on April 3, 2008.
  • 2The agreement is a Manufacturing and Supply Agreement with PTG Medical LLC.
  • 3DexCom will exclusively purchase specific polymers from PTG for synthesizing polymeric membranes used in the SEVEN system.
  • 4The agreement grants DexCom an exclusive, worldwide, royalty-free, and irrevocable license to use the polymers in continuous glucose monitoring.
  • 5The supply agreement has a term of three years.
  • 6This agreement secures a critical component for DexCom's SEVEN continuous glucose monitoring system.

Frequently Asked Questions

The 8-K filing reports on a material definitive agreement that DexCom, Inc. has entered into with PTG Medical LLC.

DexCom is securing an exclusive supply of specific polymers and an exclusive, worldwide license to use these polymers in the field of continuous glucose monitoring, which are essential for their SEVEN system.

The Manufacturing and Supply Agreement with PTG Medical LLC has a term of three years.

PTG Medical LLC is the supplier of the specialized polymers that DexCom will exclusively purchase for its continuous glucose monitoring technology.